Investors presentation February 2017 Disclaimer 2 The information - - PowerPoint PPT Presentation

investors presentation
SMART_READER_LITE
LIVE PREVIEW

Investors presentation February 2017 Disclaimer 2 The information - - PowerPoint PPT Presentation

Investors presentation February 2017 Disclaimer 2 The information included in this presentation is a summary only and performance, or achievements to be materially different from those does not exhaust all of the information on the Company and


slide-1
SLIDE 1

Investors presentation

February 2017

slide-2
SLIDE 2

2

Disclaimer

The information included in this presentation is a summary only and does not exhaust all of the information on the Company and its business, nor is it a substitute for inspection of the Periodic Report for 2015, the quarterly reports for 2016, the Company’s current reports and the presentations released thereby, as reported to the ISA via the Magna distribution site. The presentation does not constitute an

  • ffering or an invitation to purchase securities of the Company, and

the provisions thereof do not constitute a recommendation or opinion

  • r substitute for the discretion of the investor. The Company is not

responsible for the integrity or accuracy of the information. This presentation includes forecasts, estimates, assessments and other information pertaining to future events and/or matters, whose materialization is uncertain and is beyond the Company’s control, and which constitute forward-looking information, as defined in the Securities Law, 5728-1968. Such information may not materialize, in whole or in part, or may materialize in a manner significantly different to that forecast. Such information includes, inter alia, statements relating to our objectives, plans, and strategies; statements that contain projections of results of operations or of financial condition; statements relating to the research, development, and use of our technologies, products and product candidates; and all statements (other than statements of historical facts) that address activities, events, or developments that we intend, expect, project, believe, or anticipate will or may occur in the future. Forward-looking statements are not guarantees of future performance and are subject to risks and

  • uncertainties. We have based these forward-looking statements on

assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments, and other factors they believe to be appropriate. Important factors that could cause actual results, developments, and business decisions to differ materially from those anticipated in these forward-looking statements include, among

  • ther things: the overall global economic environment; the impact of

competition and new technologies; general market, political, and economic conditions in the countries in which we operate; projected capital expenditures and liquidity; changes in our strategy; government regulations and approvals; litigation and regulatory proceedings. These statements are only current predictions and are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from those anticipated by the forward-looking statements. We discuss many of these risks in the “Risk Factors” section and elsewhere in the Registration Statement on Form F-1 filed with the U.S. Securities and Exchange Commission and in the Periodical reports (in Hebrew) with the Israeli Security Authority and the Tel Aviv Stock Exchange. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Except as required by law, we are under no duty to update or revise any of the forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this

  • prospectus. These forward-looking statements speak only as of the

date of this presentation, and we assume no obligation to update or revise these forward-looking statements for any reason. The information presented was prepared according to the past experience and professional knowledge accumulated by the Company and in good faith. Such information is presented below for the sake of convenience only, but is not a substitute for the information provided by the Company in its financial statements or its immediate reports or in connection therewith, and therefore should not be relied on solely in itself. The information included in this presentation is similar to the information included in the reports and/or immediate reports of the Company and does not include new material information. However, some of the data included in the presentation are presented in a different manner and/or breakdown and/or are differently edited. In any event of inconsistency between the reports and/or immediate reports of the Company released to the public and the information contained in this presentation, the information released to the public as aforesaid shall prevail. All figures are approximate.

slide-3
SLIDE 3

3

Overview

  • We are a regenerative medicine company focused on developing and

commercializing products for the orthobiologics and wound care markets

  • Our technology allows the cost-efficient production of high quality

recombinant human collagen (rhCollagen)

  • Our two lead products have received CE marking, and product launches

across Europe have been initiated

  • We entered into an agreement with Arthrex, a leading orthopedic company,

for European distribution of VergenixSTR for the treatment of tendonitis

  • We are co-developing a surgical matrix with Bioventus, a global leader in

active orthopedic healing, to address a $1.8 billion opportunity in spinal surgery and trauma

slide-4
SLIDE 4

Yehiel Tal CEO

  • Regentis

Biomaterials

  • ProChon Biotech
  • Kulicke & Soffa

Industries Oded Shoseyov Prof./Founder/CSO

  • Pauli Clean Tech
  • CBD Tech.
  • Fulcrum-SPD
  • Melodea
  • Hebrew University

Eran Rotem CFO

  • Tefron, CFO

(NYSE,TASE)

  • Healthcare Tech.,

CFO (NASDAQ) &Gamida, CFO

  • E&Y

Experienced management team

Philippe Bensimon VP RA/QA/CA

  • Maquet-Getinge
  • 3M Medical

Shomrat Shurtz

VP Commercialization

  • Protalix
  • BBDO Proximity
  • Clal holdings

4

Nadav Orr, PhD VP R&D

  • Ethicon

Biosurgery, Johnson & Johnson Ilan Belzer COO

  • BioHarvest
  • Procognia Ltd.
  • Omrix

Biopharmaceuticals

  • Interpharm
slide-5
SLIDE 5

5

Surgical Matrix

Spine fusion & trauma

Soft Tissue Repair Matrix

Tendinopathy

Wound Filler

Chronic & surgical wounds

Wound care Orthopedics

$1.8B $2.0B $3.0B

Annual market potential

5

Our products

slide-6
SLIDE 6

6

Field Product candidate Indications Annual market potential Stage of development

Commercialization

Upcoming milestones Discovery Preclinical Clinical Regulatory

Wound care

Chronic & surgical wounds $3.0B

Pre-IDE submission for Surgical Wounds indication

Orthobiologics

Tendonitis $2.0B

Commercialization in EU with Arthrex Pre-IDE submission

Orthobiologics

CollPlant Surgical Matrix Spine fusion & trauma $1.8B

IND submission (FDA) by Bioventus

3D Bioprinting

BioInk Cornea & cardiac patch Partnered Wholly-Owned

Europe US Europe US US

Pipeline with multiple value drivers

slide-7
SLIDE 7

7

Recent accomplishments and planned upcoming milestones

Recent accomplishments:

  • Initial distributors established for VergenixFG and sales commenced
  • Positive clinical results of VergenixSTR
  • VergenixSTR CE mark received
  • VergenixSTR distribution agreement with Arthrex for pan-European sales
  • Commenced sales of VergenixSTR

Planned upcoming milestones:

  • Sign Definitive agreement with Bioventus *
  • Successful EU market launch of VergenixSTR (with Arthrex)
  • Expansion of VergenixFG distribution network from 2 to 6 territories in EU
  • Completion of EU Post Marketing Surveillance study with VergenixFG (50 subjects)
  • Initiate FDA process (e.g. pre-IDE meeting) with VergenixSTR
  • Signing new co-development agreement with a partner (e.g. BioInk, Orthopedics)

* While the co-development activity is ongoing, no license and supply agreement has been entered into and there can be no assurance that we

will enter into any definitive agreement with Bioventus. In anticipation of filing an IND, Bioventus is undertaking preclinical animal studies comparing the Collplant Surgical Matrix to other active comparators, and could decide to move forward with a competing product

slide-8
SLIDE 8

8

CollPlant’s technology: cost effective and scalable production

GROWING EXTRACTION PURIFICATION & FILLING END PRODUCT FABRICATION

Clean room facility Low cost space

Leaves Protein Concentrate Collagen PLANTLETS IN NURSERY Plant

Low cost scalable seed propagation

slide-9
SLIDE 9

9

kit

PRP collection tube from any commercial PRP Kit

Plasma Platelet-Rich Plasma Red Blood Cells

slide-10
SLIDE 10

10

Study results

Study Design

  • Significant potential advantages over SoC

Clinical trial results

Study Results

  • Single arm study
  • 40 patients with tennis elbow (tendinopathy)
  • One single treatment
  • 3- and 6-month follow up
  • End points – Safety; recovery in pain and motion as

measured through PRTEE, Quality of Life questionnaire and grip strength test

  • f patients show clinical success at 3M
  • f patients show clinical success at 6M

74% 86%

48% 36%

6M 3M

74% 86%

6M 3M

slide-11
SLIDE 11

11

Tendon repair - injectable rhCollagen/PRP matrix intended for treatment of partial or full

tendon tears

  • Based on VergenixSTR technology
  • Annual US incidents: ~400K
  • RCR1, ACL2, Achilles3

rhCollagen-PRP clot

11

Future opportunity for VergenixSTR

  • 1. http://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/1471-2474-15-4
  • 2. http://orthosurg.ucsf.edu/patient-care/divisions/sports-medicine/conditions/knee/anterior-cruciate-ligament-injury-acl/
  • 3. http://www.uptodate.com/contents/achilles-tendinopathy-and-tendon-rupture
slide-12
SLIDE 12

12

kit

slide-13
SLIDE 13

13

Study results

Study Design

Clinical trial results

  • 1. “The efficacy and safety of Grafix for the treatment of chronic diabetic foot ulcers: results of

a multicenter, controlled, randomized, blinded clinical trial,” Lavery et al, International Wound Journal, 2014.

Study Results

  • Single arm study
  • 20 patients with lower limb ulcer
  • One single treatment
  • 4 week follow up
  • End points – Safety; wound reduction
  • Average wound closure rate of 80%
  • Full wound closure was observed in nine of the 20

patients (45%)

  • Versus 24% of patients after 12 weeks with SoC1
  • Full wound closure at 4 weeks after a single treatment

30% 62% 67% 80%

0% 10% 20% 30% 40% 50% 60% 70% 80% 90% Week 1 Week 2 Week 3 Week 4

Mean Wound Closure Rate (%) over time (N=20 patients)

slide-14
SLIDE 14

14

Sales & marketing strategy: Europe first

  • Due to rapid marketing clearance, Europe offers an opportunity to accelerate

revenue realization and develop a physician base of experience

  • Utilize established distributors selling orthobiologics and wound care products

across Europe in key markets

  • Undertake Post Marketing Surveillance (PMS) studies with KOLs generate

additional clinical data to support product sales and reimbursement

  • Post Marketing Surveillance: 50+ cases to support conference presentations and peer-

reviewed journal submissions

  • EMEA partnership with Arthrex extends potential for VergenixSTR beyond Europe

into Middle East & African markets

  • FDA regulatory strategy informed by European regulatory and clinical experience
  • Establish KOL network to support EU market penetration
  • Strategic collaborations provide pipeline and market expansion opportunities,

leveraging partner infrastructure to drive adoption of rhCollagen

slide-15
SLIDE 15

15 15

CollPlant Surgical Matrix for bone repair Collaboration with Bioventus Inc.

* http://www.boneandjointburden.org/2014-report/iie1/spinal-fusion http://www.startribune.com/medtronic-s-infuse-widely-used-despite-cost-risks/49557847/

  • We are party to a non-binding term sheet

entered into on July 2015 with Bioventus for the license and supply of the CollPlant Surgical Matrix

  • The surgical matrix enables targeted and

controlled release of BMP-2 for accelerated bone formation

  • Applications: spinal fusion and trauma
  • Addressable market opportunity is projected to

be at least $1.8 billion (450,000 procedures*)

  • The surgical matrix is co-developed by the

companies, with our aim to sign a Definitive Agreement in FY 2017

While the co-development activity is ongoing, no license and supply agreement has been entered into and there can be no assurance that we will enter into any definitive agreement with Bioventus. In anticipation of filing an IND, Bioventus is undertaking preclinical animal studies comparing the Collplant Surgical Matrix to other active comparators, and could decide to move forward with a competing product

slide-16
SLIDE 16

16

Future opportunity: BioInk

1 https://www.grandviewresearch.com/press-release/global-3d-bioprinting-market

rhCollagen-based BioInk for 3D bioprinting of tissues & organs

 Market potential: $1B+ by 20221  CollPlant’s rhCollagen-based BioInk offers ideal characteristics for 3D bioprinting

 Biocompatible – supports cell viability  Controlled degradation profile  Optimized viscosity and gelation kinetics  Printed construct maintains physical properties compatible with natural tissue

slide-17
SLIDE 17

17

CollPlant IP portfolio

Patent Name Application # Priority Date Patent Status Collagen Producing Plants and Methods

  • f Generating and Using Same

WO2006/035442 9/2004 Granted: USA(CIP), Europe, Europe(DIV-1), Europe(DIV-2allowed), Hong Kong ,Hong Kong(DIV) ,Canada, Japan Japan(DIV), Australia (DIV-1), Australia (DIV-2), Mexico, China, South Africa, , Singapore, India, Israel, New Zealand. Pending: USA (DIV), Brazil, Europe(DIV), India(DIV) Compositions Comprising Fibrous Polypeptides and Polysaccharides WO2009069123 11/2007 Granted: USA,USA(DIV-1), USA(DIV-2), USA(DIV- 3), Australia, Israel, Israel(DIV-Published), Europe Pending: USA(CON) Methods of Generating Collagen Fibers WO2011/064773 11/2009 Pending: Europe, USA, Hong Kong Methods of Generating and Using Procollagen WO2009/128076 4/2008 Granted: USA,Europe, Israel Pending:Canada, China(DIV), India, USA(CON) Methods of Processing Recombinant Procollagen WO2009/053985 10/2007 Granted: USA, Israel, Europe Compositions comprising collagen and PRP for tissue regeneration WO2014/147622 3/2013 Pending: USA, Europe, Canada, China, India, Israel Cross-linked Resilin-containing materials W2015/068160 1/2013 Pending: USA, Europe, Canada, China, India, Israel Adhesive biopolymers and uses thereof WO2013/030840 9/2011 Pending: USA, Europe, Israel

slide-18
SLIDE 18

18

Only viable technology currently available that can produce truly human collagen Multi-billion dollar market: innovative rhCollagen products initially aimed at orthopedics and wound healing Near-term revenues: Bioventus license milestone payments and commercialization of two lead products in Europe in 2017 Broadly applicable technology: future indications may include BioInk for 3D Bioprinting, ACL repair and surgical wounds Strong IP position Proven management team

CollPlant investment highlights

slide-19
SLIDE 19

February 2017